Chemotherapy-induced nausea and vomiting

Global Cannabis Testing Market 2023 to 2035: Growing Demand for Cannabis Legalization and Cannabis-infused Products Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 9, 2023
Cannabis, Natural Resources, COVID-19, Reform, Cannabinoid, National Organization for the Reform of Marijuana Laws, Type, Sale, Pesticide, Chemotherapy-induced nausea and vomiting, Chronic pain, Safety, Drug

This report features an extensive study of the current market landscape and the likely future potential of the cannabis testing market, over the next 12 years.

Key Points: 
  • This report features an extensive study of the current market landscape and the likely future potential of the cannabis testing market, over the next 12 years.
  • In the last few years, several countries across the globe have legalized the use of medical cannabis and recreational-use cannabis / adult-use cannabis.
  • This can be attributed to the therapeutic potential of cannabis and cannabis-infused products that has been acknowledged recently.
  • Specifically, in terms of type of cannabis tested, the market is anticipated to be driven by the high demand for medicinal cannabis.

KoreConX and Cannabis Wiki Educate Entrepreneurs on How to Raise Capital

Retrieved on: 
星期二, 十月 4, 2022
Patient, GLOBE, Compliance, Investment, Acquisition, CEO, Partnership, CAGR, Lists of diseases, USD, Cannabis, Chemotherapy-induced nausea and vomiting, Chronic pain, Drug, Security (finance)

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- KoreConX and Cannabis Wiki are now working closely together to help the cannabis sector grow.

Key Points: 
  • NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- KoreConX and Cannabis Wiki are now working closely together to help the cannabis sector grow.
  • Cannabis Wiki and KoreConX will start a series of content products to help educate these entrepreneurs.
  • Derrick Berney, CEO and co-founder of Cannabis Wiki, is excited to see this partnership grow: "No one does what KoreConX does.
  • Their materials, blogs, podcasts, they are really changing the way startups raise capital and the cannabis sector needs it.

Chemotherapy Induced Nausea and Vomiting Epidemiology Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
星期三, 八月 3, 2022
Health, Oncology, Classification, Diagnosis, United Kingdom, Chemotherapy-induced nausea and vomiting, Disease, Table, Overview, Epidemiology, Nausea, Platinum, Pharmaceutical industry, Vomiting

This "Chemotherapy Induced Nausea and Vomiting - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Nausea and Vomiting epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Chemotherapy Induced Nausea and Vomiting - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Nausea and Vomiting epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Chemotherapy Induced Nausea and Vomiting epidemiology report gives a thorough understanding of the Chemotherapy Induced Nausea and Vomiting by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The Chemotherapy Induced Nausea and Vomiting epidemiology covered in the report provides historical as well as forecasted Chemotherapy Induced Nausea and Vomiting epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Chemotherapy Induced Nausea and Vomiting report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Chemotherapy Induced Nausea and Vomiting Epidemiology Report and Model provide an overview of the global trends of Chemotherapy Induced Nausea and Vomiting in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Chemotherapy Induced Nausea and Vomiting in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
    Quantify patient populations in the global Chemotherapy Induced Nausea and Vomiting market to improve product design, pricing, and launch plans
    The Chemotherapy Induced Nausea and Vomiting Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

Tilray Expands Medical Cannabis Product Offering in Australia

Retrieved on: 
星期二, 一月 25, 2022
TGA, Nasdaq, Physician, Forward-looking statement, Partnership, Energy drink, Securities Exchange Act of 1934, SEC, Research, Clinical trial, Chemotherapy-induced nausea and vomiting, Drug Quality and Security Act, Health, Therapeutic Goods Administration, University, TSX, Cannabis, University of Sydney, Industry, Securities Act of 1933, Achievement, Company, Annual report, General manager, Communication, Goal, Hospital, Intellectual, GMP, Pharmacy, Authorization, Patient, EDGAR, International, THC, Â, GLOBE, Drug, Medicinal plants, Tilray

NEW YORK and SYDNEY, Australia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for healthcare providers.

Key Points: 
  • NEW YORK and SYDNEY, Australia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for healthcare providers.
  • As medical cannabis demand increases worldwide, we remain committed to providing healthcare professionals and patients with safe and reliable access to the highest-quality medical cannabis products.
  • George Polimenakos, General Manager, Tilray Australia, and New Zealand, said, "We are committed to providing reliable access to patients in need with pharmaceutical-grade medical cannabis products and are pleased to be expanding our medical cannabis offerings in Australia."
  • Tilrays new medical cannabis educational platform for healthcare professionals is built on the importance of understanding the benefits derived from medical cannabis use.

Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study

Retrieved on: 
星期三, 六月 16, 2021
Serotonin antagonists, Receptor antagonists, Drugs, Oncology, Vomiting, Atypical antipsychotics, Chemotherapy-induced nausea and vomiting, Antiemetic, Olanzapine, Nausea, Endpoint, Clinical endpoint

Total Control is a measure of no nausea, no vomiting, and no rescue medications; existing antiemetics have been approved using a Complete Response (CR) endpoint which only measures vomiting and rescue medications.

Key Points: 
  • Total Control is a measure of no nausea, no vomiting, and no rescue medications; existing antiemetics have been approved using a Complete Response (CR) endpoint which only measures vomiting and rescue medications.
  • The largest and most comprehensive meta-analysis of the use of olanzapine in CINV was published a few months ago (Chow 2021).
  • The meeting provided guidance for the design of the planned Phase 2 clinical study and endpoint strategy, as well as planned work to support the validation of a nausea scale.
  • Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements.

Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China

Retrieved on: 
星期一, 三月 1, 2021
Clinical medicine, Medicine, Branches of biology, Oncology, Antineoplastic drugs, Chemotherapy-induced nausea and vomiting, Vomiting, Cancer treatments, Antiemetics, Chemotherapy, Nausea

Starton and Haisco are preparing to launch clinical studies in chemotherapy induced nausea and vomiting (CINV), followed by additional nausea and vomiting indications.

Key Points: 
  • Starton and Haisco are preparing to launch clinical studies in chemotherapy induced nausea and vomiting (CINV), followed by additional nausea and vomiting indications.
  • Pedro Lichtinger, CEO of Starton Therapeutics, commented, Haisco is an ideal partner for our STAR-OLZ product.
  • In addition to being a respected pharmaceutical company in China, Haisco leads in antiemetic sales in China and has several antiemetics products in the market and in development.
  • Junmin Wang, Chairman of Haisco Board, commented, Haisco has built a strong profile in tumor antiemetic area.

Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor

Retrieved on: 
星期一, 十二月 7, 2020
Cancer, Clinical medicine, Oncology, Medicine, Antineoplastic drugs, Chemotherapy-induced nausea and vomiting, Chemotherapy, Breast cancer

The first abstract presents findings from an evaluation of individual patients risk of repeat CINV in each subsequent chemotherapy cycle in breast cancer patients.

Key Points: 
  • The first abstract presents findings from an evaluation of individual patients risk of repeat CINV in each subsequent chemotherapy cycle in breast cancer patients.
  • Our second abstract demonstrated that CINV duration (short vs extended) in cycle 1 strongly predicted CINV recurrence in subsequent cycles.
  • Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.
  • Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment.

IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol

Retrieved on: 
星期三, 十月 21, 2020
Clinical medicine, Medicine, Appetite stimulants, Antiemetics, Medical specialties, Aromatase inhibitors, Entheogens, Euphoriants, Dronabinol, Tetrahydrocannabinol, Chemotherapy-induced nausea and vomiting, Chemotherapy

The Adversa technology is designed to limit first-pass metabolism, improve bioavailability, enhance product stability and reduce gastro-intestinal exposure and side-effects.

Key Points: 
  • The Adversa technology is designed to limit first-pass metabolism, improve bioavailability, enhance product stability and reduce gastro-intestinal exposure and side-effects.
  • Tetra will use the Adversa technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.
  • In addition, Tetra will pay IntelGenx a low single digit royalty on future net sales of Dronabinol mucoadhesive tablets.
  • This agreement reflects the many potential therapeutic benefits of our Adversa delivery technology, said Dr.Horst G. Zerbe, CEO ofIntelGenx.

Tilray Medical Cannabis Product Shows Promise Reducing Nausea and Vomiting Caused by Chemotherapy in World First Clinical Trial

Retrieved on: 
星期一, 九月 28, 2020
Oncology, Alternative medicine, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Health, Oncology, Antiemetics, Antineoplastic drugs, Vomiting, Cancer treatments, Tilray, Chemotherapy-induced nausea and vomiting, Medical cannabis, Chemotherapy

Results published in Annals of Oncology found a significant improvement in the control of chemotherapy-induced nausea and vomiting.

Key Points: 
  • Results published in Annals of Oncology found a significant improvement in the control of chemotherapy-induced nausea and vomiting.
  • A quarter of the patients taking medicinal cannabis experienced no vomiting and nausea, compared to 14 percent of people who took a placebo.
  • To be included in the study, patients had to have already experienced nausea and vomiting during chemotherapy despite having taken nausea prevention medication.
  • Tilray is supplying the product for the trial, which is being funded by the NSW government.

Chemotherapy-induced Nausea & Vomiting Drugs Market, 2024 - Focus on Serotonin & NK1 Receptor Antagonists and Other Therapies

Retrieved on: 
星期三, 八月 12, 2020
Clinical medicine, Medicine, Medical specialties, Oncology, Antineoplastic drugs, Cancer treatments, Antiemetics, Chemotherapy-induced nausea and vomiting, Chemotherapy, Nausea, Vomiting

DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global chemotherapy-induced nausea and vomiting drugs market is poised to grow by $525 million during 2020-2024, progressing at a CAGR of 5% during the forecast period.
  • The study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.
  • The chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes.